Gregerson Celestine H Yeung, Bakian Amanda V, Wilkes Jacob, Knighton Andrew J, Nkoy Flory, Sweney Matthew, Filloux Francis M, Bonkowsky Joshua L
School of Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
Department of Psychiatry, Salt Lake City, UT, USA.
J Child Neurol. 2019 Dec;34(14):928-936. doi: 10.1177/0883073819866623. Epub 2019 Sep 10.
The purpose of our study was to assess whether race/ethnicity was associated with seizure remission in pediatric epilepsy.
This was a retrospective population-based cohort study of children who were evaluated for new-onset epilepsy in the clinic, emergency department, and/or hospital by a pediatric neurologist in an integrated health care delivery system. Children were between ages 6 months and 15 years at their initial presentation of epilepsy. The cohort, identified through an electronic database, was assembled over 6 years, with no less than 5 years of follow-up. All children were evaluated for race, ethnicity, insurance type, and socioeconomic background. Patient outcome was determined at the conclusion of the study period and categorized according to their epilepsy control as either drug resistant (pharmacoresistant and intractable) or drug responsive (controlled, probable remission, and terminal remission).
In the final cohort of 776 patients, 63% were drug responsive (control or seizure remission). After controlling for confounding socioeconomic and demographic factors, children of Hispanic ethnicity experienced reduced likelihood (hazard) of drug-responsive epilepsy (hazard ratio 0.6, < .001), and had longer median time to remission (8 years; 95% CI 5.9-9.6 years) compared to white non-Hispanic patients (5.6 years; 95% CI 4.9-6.1 years). Among Hispanic patients, higher health care costs were associated with reduced likelihood of drug responsiveness.
We found that Hispanic ethnicity is associated with a reduced likelihood of achieving seizure control and remission. This study suggests that factors associated with the race/ethnicity of patients contributes to their likelihood of achieving seizure freedom.
我们研究的目的是评估种族/族裔是否与小儿癫痫的发作缓解有关。
这是一项基于人群的回顾性队列研究,研究对象是在综合医疗服务系统中由儿科神经科医生在诊所、急诊科和/或医院接受新发癫痫评估的儿童。儿童在首次出现癫痫时年龄在6个月至15岁之间。通过电子数据库确定队列,该队列在6年内组建完成,随访时间不少于5年。对所有儿童进行种族、族裔、保险类型和社会经济背景评估。在研究期结束时确定患者结局,并根据癫痫控制情况将其分类为耐药(药物抵抗和难治性)或药物反应性(控制、可能缓解和最终缓解)。
在最终的776例患者队列中,63%为药物反应性(控制或发作缓解)。在控制了混杂的社会经济和人口统计学因素后,与非西班牙裔白人患者相比,西班牙裔儿童发生药物反应性癫痫的可能性(风险)降低(风险比0.6,P<0.001),缓解的中位时间更长(8年;95%CI 5.9 - 9.6年)(非西班牙裔白人患者为5.6年;95%CI 4.9 - 6.1年)。在西班牙裔患者中,较高的医疗费用与药物反应性降低相关。
我们发现西班牙裔与癫痫发作控制和缓解的可能性降低有关。这项研究表明,与患者种族/族裔相关的因素有助于其实现无癫痫发作的可能性。